347 related articles for article (PubMed ID: 19337272)
1. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes.
Baxter JD; Webb P
Nat Rev Drug Discov; 2009 Apr; 8(4):308-20. PubMed ID: 19337272
[TBL] [Abstract][Full Text] [Related]
2. Lipid lowering with thyroid hormone and thyromimetics.
Angelin B; Rudling M
Curr Opin Lipidol; 2010 Dec; 21(6):499-506. PubMed ID: 20935564
[TBL] [Abstract][Full Text] [Related]
3. Thyroid Hormone Mimetics: the Past, Current Status and Future Challenges.
Elbers LP; Kastelein JJ; Sjouke B
Curr Atheroscler Rep; 2016 Mar; 18(3):14. PubMed ID: 26886134
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms in endocrinology: the crosstalk between thyroid gland and adipose tissue: signal integration in health and disease.
Santini F; Marzullo P; Rotondi M; Ceccarini G; Pagano L; Ippolito S; Chiovato L; Biondi B
Eur J Endocrinol; 2014 Oct; 171(4):R137-52. PubMed ID: 25214234
[TBL] [Abstract][Full Text] [Related]
5. Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.
Parthsarathy V; Hogg C; Flatt PR; O'Harte FPM
Diabetes Obes Metab; 2018 Feb; 20(2):319-327. PubMed ID: 28730728
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus.
Dostálová I; Haluzíková D; Haluzík M
Physiol Res; 2009; 58(1):1-7. PubMed ID: 19331512
[TBL] [Abstract][Full Text] [Related]
7. Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141.
Bryzgalova G; Effendic S; Khan A; Rehnmark S; Barbounis P; Boulet J; Dong G; Singh R; Shapses S; Malm J; Webb P; Baxter JD; Grover GJ
J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):262-7. PubMed ID: 18621127
[TBL] [Abstract][Full Text] [Related]
8. [The pharmacological treatment of obesity: past, present and future].
Simonyi G; Pados G; Medvegy M; Bedros JR
Orv Hetil; 2012 Mar; 153(10):363-73. PubMed ID: 22370224
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
10. [The pharmacotherapy of obesity].
Budai KA; Mirzahosseini A; Noszál Béla ; Tóth G
Acta Pharm Hung; 2015; 85(1):3-17. PubMed ID: 26137782
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential for thyroid hormone receptor-beta selective agonists for treating obesity, hyperlipidemia and diabetes.
Grover GJ; Mellström K; Malm J
Curr Vasc Pharmacol; 2007 Apr; 5(2):141-54. PubMed ID: 17430219
[TBL] [Abstract][Full Text] [Related]
12. Thyroid hormones and treatment of obesity.
Krotkiewski M
Int J Obes Relat Metab Disord; 2000 Jun; 24 Suppl 2():S116-9. PubMed ID: 10997625
[TBL] [Abstract][Full Text] [Related]
13. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
Iepsen EW; Torekov SS; Holst JJ
Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
[TBL] [Abstract][Full Text] [Related]
14. Thyroid hormone metabolites and analogues.
Senese R; Cioffi F; Petito G; Goglia F; Lanni A
Endocrine; 2019 Oct; 66(1):105-114. PubMed ID: 31359245
[TBL] [Abstract][Full Text] [Related]
15. Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease.
Finan B; Clemmensen C; Zhu Z; Stemmer K; Gauthier K; Müller L; De Angelis M; Moreth K; Neff F; Perez-Tilve D; Fischer K; Lutter D; Sánchez-Garrido MA; Liu P; Tuckermann J; Malehmir M; Healy ME; Weber A; Heikenwalder M; Jastroch M; Kleinert M; Jall S; Brandt S; Flamant F; Schramm KW; Biebermann H; Döring Y; Weber C; Habegger KM; Keuper M; Gelfanov V; Liu F; Köhrle J; Rozman J; Fuchs H; Gailus-Durner V; Hrabě de Angelis M; Hofmann SM; Yang B; Tschöp MH; DiMarchi R; Müller TD
Cell; 2016 Oct; 167(3):843-857.e14. PubMed ID: 27720451
[TBL] [Abstract][Full Text] [Related]
16. The effect of thyroid disorders on lipid levels and metabolism.
Duntas LH; Brenta G
Med Clin North Am; 2012 Mar; 96(2):269-81. PubMed ID: 22443975
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of diabetes and atherosclerosis: role of adiponectin.
Kishida K; Funahashi T; Shimomura I
Endocr Metab Immune Disord Drug Targets; 2012 Jun; 12(2):118-31. PubMed ID: 22236026
[TBL] [Abstract][Full Text] [Related]
18. Do thyroid hormones play a role in the treatment of obesity?
Meinders AE
Neth J Med; 1981; 24(3):124-7. PubMed ID: 7254444
[No Abstract] [Full Text] [Related]
19. The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism.
Eleftheriadou I; Grigoropoulou P; Katsilambros N; Tentolouris N
Curr Diabetes Rev; 2008 Nov; 4(4):340-56. PubMed ID: 18991602
[TBL] [Abstract][Full Text] [Related]
20. Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs?
Flatt PR
Diab Vasc Dis Res; 2007 Jun; 4(2):151-3. PubMed ID: 17654450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
